Valuation: Verastem, Inc.

Market Cap 759M 678M 631M 574M 1.08B 73.45B 1.09B 7.59B 2.97B 37.45B 2.85B 2.79B 120B P/E 2026 *
-5.1x
P/E 2027 * -7.19x
Enterprise Value 801M 715M 665M 605M 1.14B 77.5B 1.15B 8.01B 3.14B 39.51B 3.01B 2.94B 127B EV / Sales 2026 *
6.9x
EV / Sales 2027 * 4.21x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
07/10 B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating MT
29/09 Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer CI
19/09 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
17/09 Wolfe Research Initiates Verastem at Outperform MT
14/09 RTW Biotech NAV rises 15% as public investments drive returns AN
08/09 Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers CI
11/08 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
08/08 Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million CI
07/08 Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026
07/08 Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
29/07 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer CI
23/07 Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer CI
07/07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
1 day+3.33%
1 week+8.83%
Current month+4.10%
1 month+9.97%
3 months+51.54%
6 months+57.82%
Current year+8.55%
1 week 7.52
Extreme 7.52
8.58
1 month 7.2
Extreme 7.195
8.64
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Sell

Chief Financial Officer

-2,566 0.0042%
1/10/26 Sell

Chief Executive Officer

-44,121 0.0717%
21/9/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+3.33%+8.83%-2.22%+3.97% 759M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +1.08%-1.51%+44.43%+100.28% 37.73B
Weighted average by Cap. +0.56%-2.92%+51.24%+115.35%

Financials

2026 *2027 *
Net sales 116M 104M 96.41M 87.7M 166M 11.23B 166M 1.16B 455M 5.73B 436M 426M 18.37B 180M 161M 150M 136M 257M 17.46B 259M 1.8B 707M 8.9B 677M 663M 28.57B
Net income -166M -148M -138M -126M -237M -16.08B -238M -1.66B -651M -8.2B -624M -610M -26.31B -158M -141M -131M -119M -225M -15.26B -226M -1.58B -618M -7.78B -592M -579M -24.97B
Net Debt 41.9M 37.42M 34.81M 31.66M 59.78M 4.06B 60.04M 419M 164M 2.07B 157M 154M 6.63B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
09/10/26 USD 8.380 +3.33% 2,970,338
08/10/26 USD 8.110 -1.88% 3,051,551
07/10/26 USD 8.265 +6.65% 3,928,558
06/10/26 USD 7.750 -3.12% 2,513,883
05/10/26 USD 8.000 +3.90% 2,217,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.380USD
Average target price
15.00USD
Spread / Average Target
+79.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock